Dr. Jeremy Nettleton

Dr. Jeremy Nettleton
Mr. Nettleton completed his undergraduate training at Guy’s, Kings and St Thomas’ Hospitals, London. His surgical training was completed in London and the South West of England. He was the first chief resident at Bristol Urological Institute and completed a fellowship there in renal surgery and endourology. Jeremy was appointed to Gloucestershire Hospitals NHS Foundation Trust in October 2020, he is currently clinical lead for the department. He continues to push for improved care for his patients and recently led the successful bid for two new DaVinci robots and a fixed site lithotripter for Gloucestershire hospitals. He has a passion for improving his own practice and that of the department. He has a high volume practice and has outstanding clinical outcomes as measured by national metrics. He has an excellent and published track record in quality improvement leading to nationally leading outcomes in these areas. In addition, he has done advisory work for the National Institute for Clinical Excellence, Olympus Medical, Procept and the International Incontinence Society. Mr. Nettleton regularly leads national webinars, aiding others to improve their practice. Mr. Nettleton is published, has written book chapters and has presented widely. He has an ongoing active interest in research and medical education. Jeremy was the first surgeon to complete Aquablation in the South West region and works with Procept on day case pathways.
Medical School:

Guy's King's and St. Thomas' Hospitals Medical School

Fellowship:

Bristol Urological Institute

Locations

Winfield Hospital, Gloucester Longford, Gloucester,

Tewkesbury RdLongford, Gloucester, GL2 9WHUnited Kingdom
01452 945213 | Visit Website

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only